Enzalutamide-induced “BRCAness” and PARP inhibition is a synthetic lethal therapy for castration-resistant prostate cancer

Cancers with dysfunctional mutations in BRCA1 or BRCA2, most commonly associated with some breast cancers, are deficient in the DNA damage repair pathway called homologous recombination (HR), which makes them exquisitely vulnerable to poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib....

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Sci Signal
Κύριοι συγγραφείς: Li, Likun, Karanika, Styliani, Yang, Guang, Wang, Jiangxiang, Park, Sanghee, Broom, Bradley, Manyam, Ganiraju C., Wu, Wenhui, Luo, Yong, Basourakos, Spyridon, Song, Jian H., Gallick, Gary E., Karantanos, Theodoros, Korentzelos, Dimitrios, Azad, Abul Kalam, Kim, Jeri, Corn, Paul G., Aparicio, Ana M., Logothesis, Christopher J., Troncoso, Particia, Timothy, Heffernan, Toniatti, Carlo, Lee, Hyun-Sung, Lee, Ju-Seog, Zuo, Xuemei, Chang, Wenjun, Yin, Jianhua, Thompson, Timothy C.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5855082/
https://ncbi.nlm.nih.gov/pubmed/28536297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aam7479
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια